Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci USA

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 11/2006; 103(43):15951-6. DOI: 10.1073/pnas.0604493103
Source: PubMed


Because of species selectivity, HIV research is largely restricted to in vitro or clinical studies, both limited in their ability to rapidly assess new strategies to fight the virus. To prospectively study some aspects of HIV in vivo, immunodeficient mice, transplanted with either human peripheral blood leukocytes or human fetal tissues, have been developed. Although these are susceptible to HIV infection, xenoreactivity, and short infection spans, resource and ethical constraints, as well as biased HIV coreceptor tropic strain infection, pose substantial problems in their use. Rag2(-/-)gamma(c)(-/-) mice, transplanted as newborns with human CD34(+) cells, were recently shown to develop human B, T, and dendritic cells, constituting lymphoid organs in situ. Here we tested these mice as a model system for HIV-1 infection. HIV RNA levels peaked to up to 2 x 10(6) copies per milliliter of plasma early after infection, and viremia was observed for up to 190 days, the longest time followed. A marked relative CD4(+) T cell depletion in peripheral blood occurred in CXCR4-tropic strain-infected mice, whereas this was less pronounced in CCR5-tropic strain-infected animals. Thymus infection was almost exclusively observed in CXCR4-tropic strain-infected mice, whereas spleen and lymph node HIV infection occurred irrespective of coreceptor selectivity, consistent with respective coreceptor expression on human CD4(+) T cells. Thus, this straightforward to generate and cost-effective in vivo model closely resembles HIV infection in man and therefore should be valuable to study virus-induced pathology and to rapidly evaluate new approaches aiming to prevent or treat HIV infection.

Download full-text


Available from: Adriano Aguzzi,
  • Source
    • "This possibility has been supported by the improved antigen-specific human T cell and antibody responses achieved when human CD34+ cells were injected in immunodeficient mice that expressed HLA molecules either by transgenesis [38], [39] or following transplantation of human thymus [40]. Nevertheless, although NSG mice receiving CD34+ cells failed to develop efficient antigen-specific immune responses [26], [30], [31], [36], [37], we found that, following immunization, engrafted human T cells responded to alloantigens, as shown by 3H-thymidine incorporation in an in vitro culture of CD4+ cells from the spleen. These findings do not exclude the possibility that other antigen recognition pathways exist [28], thus there remains a need to assess the major histocompatiblity complex (MHC) restriction of human T cells in this animal model. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by immune-mediated destruction of insulin-secreting β cells of the pancreas. Near complete dependence on exogenous insulin makes T1DM very difficult to control, with the result that patients are exposed to high blood glucose and risk of diabetic complications and/or intermittent low blood glucose that can cause unconsciousness, fits and even death. Allograft transplantation of pancreatic islets restores normoglycemia with a low risk of surgical complications. However, although successful immediately after transplantation, islets are progressively lost, with most of the patients requiring exogenous insulin within 2 years post-transplant. Therefore, there is an urgent requirement for the development of new strategies to prevent islet rejection. In this study, we explored the importance of human regulatory T cells in the control of islets allograft rejection. We developed a pre-clinical model of human islet transplantation by reconstituting NOD-scid IL2rγnull mice with cord blood-derived human CD34+ stem cells and demonstrated that although the engrafted human immune system mediated the rejection of human islets, their survival was significantly prolonged following adoptive transfer of ex vivo expanded human Tregs. Mechanistically, Tregs inhibited the infiltration of innate immune cells and CD4+ T cells into the graft by down-regulating the islet graft-derived monocyte chemoattractant protein-1. Our findings might contribute to the development of clinical strategies for Treg therapy to control human islet rejection. We also show for the first time that CD34+ cells-reconstituted NOD-scid IL2rγnull mouse model could be beneficial for investigating human innate immunity in vivo.
    PLoS ONE 03/2014; 9(3):e90387. DOI:10.1371/journal.pone.0090387 · 3.23 Impact Factor
  • Source
    • "Small animal models for HIV-1 infection such as Rag2-/-/Il2rg-/- mice (Traggiai et al., 2004) and BLT mice (Denton et al., 2008) have made significant contributions to our understanding of HIV/AIDS pathogenesis. However, the former mice show insufficient induction of an immune response against HIV-1 (Baenziger et al., 2006; An et al., 2007), while the use of latter mice has been influenced by some ethical restrictions and limited availability. On the other hand, immunologically intact transgenic mouse models are relatively straightforward and inexpensive, in which high levels of target gene expression can be easily achieved resulting in an obvious phenotype. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Attempts to create mouse models for AIDS have been hampered by species barriers in HIV-1 infection. We previously showed that the nuclear accumulation of HIV-1 preintegration complex (PIC) was suppressed in mouse cells. Lens epithelium-derived growth factor (LEDGF/p75) is a host factor identified as a binding partner of integrase (IN), and has been suggested to be involved in promoting viral integration by tethering PIC to the chromatin, which are observed as nuclear accumulation of IN by LEDGF/p75. Therefore, we here hypothesized that this host factor might act as one of the species-specific barriers in mouse cells. We generated transgenic (Tg) mice that constitutively express human (h) LEDGF/p75. The GFP-fused IN was efficiently accumulated into the nucleus of hLEDGF/p75 expressing Tg mouse embryonic fibroblast (MEF) cells in contrast to the control MEF cells. Importantly, hLEDGF/p75 Tg MEF cells were significantly more susceptible to HIV-1 infection. These results suggest that LEDGF/p75 is one of the host factors that constitute species barrier against HIV-1 in mouse cells.
    Frontiers in Microbiology 12/2013; 4:377. DOI:10.3389/fmicb.2013.00377 · 3.99 Impact Factor
  • Source
    • "We consequently investigated whether PD-1 blockade could also increase the titer of HIV-specific antibodies in chronically HIV-infected BLT mice. Several prior studies of HIV infection in other humanized mouse models found little or no production of HIV-specific IgM or IgG antibodies post-infection [45], [46], [47]. In earlier work with the BLT mouse model, we showed that these mice can generate antibodies against a number of HIV antigens after infection, but did not analyze the isotypes of the antibodies produced [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An estimated 34 million people are living with HIV worldwide (UNAIDS, 2012), with the number of infected persons rising every year. Increases in HIV prevalence have resulted not only from new infections, but also from increases in the survival of HIV-infected persons produced by effective anti-retroviral therapies. Augmentation of anti-viral immune responses may be able to further increase the survival of HIV-infected persons. One strategy to augment these responses is to reinvigorate exhausted anti-HIV immune cells present in chronically infected persons. The PD-1-PD-L1 pathway has been implicated in the exhaustion of virus-specific T cells during chronic HIV infection. Inhibition of PD-1 signaling using blocking anti-PD-1 antibodies has been shown to reduce simian immunodeficiency virus (SIV) loads in monkeys. We now show that PD-1 blockade can improve control of HIV replication in vivo in an animal model. BLT (Bone marrow-Liver-Thymus) humanized mice chronically infected with HIV-1 were treated with an anti-PD-1 antibody over a 10-day period. The PD-1 blockade resulted in a very significant 45-fold reduction in HIV viral loads in humanized mice with high CD8(+) T cell expression of PD-1, compared to controls at 4 weeks post-treatment. The anti-PD-1 antibody treatment also resulted in a significant increase in CD8(+) T cells. PD-1 blockade did not affect T cell expression of other inhibitory receptors co-expressed with PD-1, including CD244, CD160 and LAG-3, and did not appear to affect virus-specific humoral immune responses. These data demonstrate that inhibiting PD-1 signaling can reduce HIV viral loads in vivo in the humanized BLT mouse model, suggesting that blockade of the PD-1-PD-L1 pathway may have therapeutic potential in the treatment of patients already infected with the AIDS virus.
    PLoS ONE 10/2013; 8(10):e77780. DOI:10.1371/journal.pone.0077780 · 3.23 Impact Factor
Show more